Trial Profile
Phase 2 Study of Bevacizumab in Children and Adults With Neurofibromatosis Type 2 and Symptomatic Vestibular Schwannoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Glioma; Meningioma; Neurofibromatoses
- Focus Biomarker; Therapeutic Use
- 21 Mar 2016 New source found and integrated (NCT01207687).
- 21 Mar 2016 New source found and integrated (NCT01207687).
- 14 Mar 2016 Primary endpoint has been met, (Change in hearing response, defined as increased word recognition score (WRS) above the 95% critical threshold that is maintained across two sequential evaluation time points), according to the results published.